Aurinia Pharmaceuticals (AUPH) Operating Leases (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Operating Leases data on file, last reported at $2.3 million in Q1 2026.

• Quarterly Operating Leases fell 58.14% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 58.14% YoY) and the FY2025 annual result came in at $4.9 million, down 14.68% from the prior year.
• Operating Leases eased to $2.3 million in Q1 2026, from $4.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $7.8 million in Q2 2023 to a low of $2.3 million in Q1 2026.
• A 5-year average of $6.3 million and a median of $6.5 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases increased 5.82% — and 2026, when it tumbled 58.14%.
• Tracing AUPH's Operating Leases over 5 years: stood at $7.2 million in 2022, then slipped by 8.7% to $6.5 million in 2023, then slipped by 12.05% to $5.7 million in 2024, then dropped by 14.68% to $4.9 million in 2025, then tumbled by 52.69% to $2.3 million in 2026.
• The last three Operating Leases figures came in at $2.3 million (Q1 2026), $4.9 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.